These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 18249172)

  • 81. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Response of rhesus serum high density lipoproteins to cycles of diet-induced hypercholesterolemia.
    Fless GM; Juhn D; Karlin J; Rubenstein A; Scanu AM
    Arteriosclerosis; 1984; 4(2):154-64. PubMed ID: 6422917
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
    Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
    Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet.
    Merat S; Casanada F; Sutphin M; Palinski W; Reaven PD
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1223-30. PubMed ID: 10323773
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Disruption of Phospholipid Transfer Protein-Mediated High-Density Lipoprotein Maturation Reduces Scavenger Receptor BI Deficiency-Driven Atherosclerosis Susceptibility Despite Unexpected Metabolic Complications.
    Hoekstra M; van der Sluis RJ; Hildebrand RB; Lammers B; Zhao Y; Praticò D; van Berkel TJC; Rensen PCN; Kooijman S; Jauhiainen M; van Eck M
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):611-623. PubMed ID: 31941380
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice.
    Ding Y; Subramanian S; Montes VN; Goodspeed L; Wang S; Han C; Teresa AS; Kim J; O'Brien KD; Chait A
    Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1596-604. PubMed ID: 22580897
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice.
    Bell TA; Brown JM; Graham MJ; Lemonidis KM; Crooke RM; Rudel LL
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1814-20. PubMed ID: 16675724
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Amla (Emblica officinalis) extract is effective in preventing high fructose diet-induced insulin resistance and atherogenic dyslipidemic profile in ovariectomized female albino rats.
    Koshy SM; Bobby Z; Hariharan AP; Gopalakrishna SM
    Menopause; 2012 Oct; 19(10):1146-55. PubMed ID: 22692334
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
    Wang B; Shen Y; Zhai L; Xia X; Gu HM; Wang M; Zhao Y; Chang X; Alabi A; Xing S; Deng S; Liu B; Wang G; Qin S; Zhang DW
    J Lipid Res; 2021; 62():100091. PubMed ID: 34118252
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.
    Tamaki N; Ueno H; Morinaga Y; Shiiya T; Nakazato M
    J Atheroscler Thromb; 2012; 19(6):532-8. PubMed ID: 22353686
    [TBL] [Abstract][Full Text] [Related]  

  • 96. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.
    Siddiqui MS; Sterling RK; Luketic VA; Puri P; Stravitz RT; Bouneva I; Boyett S; Fuchs M; Sargeant C; Warnick GR; Grami S; Sanyal AJ
    Gastroenterology; 2013 Dec; 145(6):1271-9.e1-3. PubMed ID: 23973920
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 100. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.